



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Bapotulimab

Cat. No.:	HY-P99460
CAS No.:	2359413-58-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects ^[1] .	
In Vitro	Bapotulimab blocks the immunosuppressive effects of ILDR2 on T-cell activation. Bapotulimab is mouse/human cross-reactive, as ILDR2 has a 98% sequence identity between the extracellular domains of human and murine orthologs ^[1] . Bapotulimab (BAY-1905254; 5, 25, 100, or 500 ng/mL) promotes T-cell activation in vitro and enhance antigen-specific T-cell proliferation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Bapotulimab (BAY-1905254; 10 mg/kg; i.p.; on days 1 and 4) shows significantly increased antigen-specific T-cell proliferation and cytotoxicity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	8- to 12-week-old CD45.1-expressing C57BL/6 wild-type mice injected with OT-I transgenic T cells ^[1]
	Dosage:	10 mg/kg
	Administration:	i.p.; on days 1 and 4
	Result:	Showed significantly increased antigen-specific T-cell proliferation and cytotoxicity.

REFERENCES

[1]. Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). *Cancer Immunol Res.* 2020 Jul;8(7):895-911.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA